Home/Filings/4/0001104659-25-029914
4//SEC Filing

Gilad Oren 4

Accession 0001104659-25-029914

CIK 0001781983other

Filed

Mar 30, 8:00 PM ET

Accepted

Mar 31, 4:30 PM ET

Size

9.2 KB

Accession

0001104659-25-029914

Insider Transaction Report

Form 4
Period: 2025-03-27
Gilad Oren
DirectorPresident/CEO
Transactions
  • Award

    Stock Options (Right to Buy)

    2025-03-27+26,90026,900 total
    Exercise: $2.20Exp: 2035-03-28Common Stock (26,900 underlying)
  • Award

    Common Stock

    2025-03-27+6,725340,120 total
Holdings
  • Common Stock

    (indirect: By Daughter)
    1,200
  • Common Stock

    (indirect: By Son)
    600
Footnotes (3)
  • [F1]These shares represent restricted stock units and shall vest and be settled in the Issuer's common stock in three (3) equal annual installments beginning on March 27, 2026, until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
  • [F2]The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
  • [F3]Twenty-five percent of these options vest on March 27, 2026, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.

Issuer

Aprea Therapeutics, Inc.

CIK 0001781983

Entity typeother

Related Parties

1
  • filerCIK 0001929300

Filing Metadata

Form type
4
Filed
Mar 30, 8:00 PM ET
Accepted
Mar 31, 4:30 PM ET
Size
9.2 KB